Cargando…

Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-

BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Umezawa, Rei, Takanami, Kentaro, Kadoya, Noriyuki, Nakajima, Yujiro, Saito, Masahide, Ota, Hideki, Matsushita, Haruo, Sugawara, Toshiyuki, Kubozono, Masaki, Yamamoto, Takaya, Ishikawa, Yojiro, Takeda, Ken, Taki, Yasuyuki, Takase, Kei, Jingu, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407329/
https://www.ncbi.nlm.nih.gov/pubmed/25896887
http://dx.doi.org/10.1186/s13014-015-0410-z
_version_ 1782367890450677760
author Umezawa, Rei
Takanami, Kentaro
Kadoya, Noriyuki
Nakajima, Yujiro
Saito, Masahide
Ota, Hideki
Matsushita, Haruo
Sugawara, Toshiyuki
Kubozono, Masaki
Yamamoto, Takaya
Ishikawa, Yojiro
Takeda, Ken
Taki, Yasuyuki
Takase, Kei
Jingu, Keiichi
author_facet Umezawa, Rei
Takanami, Kentaro
Kadoya, Noriyuki
Nakajima, Yujiro
Saito, Masahide
Ota, Hideki
Matsushita, Haruo
Sugawara, Toshiyuki
Kubozono, Masaki
Yamamoto, Takaya
Ishikawa, Yojiro
Takeda, Ken
Taki, Yasuyuki
Takase, Kei
Jingu, Keiichi
author_sort Umezawa, Rei
collection PubMed
description BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with esophageal cancer before and six months after curative mediastinal RT. Single photon emission computed tomography (SPECT) images of pre-RT and post-RT were registered into RT dose distributions. The myocardium was contoured, and the regional RT dose was calculated. Normalization is required to compare pre- and post-RT SPECT images because the uptake pattern is changed due to the breathing level. Normalization was applied on the mean of SPECT counts in regions of the myocardium receiving less than 5 Gy. Relative values in each dose region (interval of 5 Gy) were calculated on the basis of this normalization for each patient. The reduction in the percent of relative values was calculated. RESULTS: Five patients were enrolled in this study. None of the patients had a past history of cardiac disease. The left ventricle was partially involved in RT fields in all patients. The patients received RT with median total doses of 60-66 Gy for the primary tumor and metastatic lymph nodes. Concomitant chemotherapy consisting of cisplatin or nedaplatin and 5-fluorouracil with RT was performed in 4 patients. All patients had reduced uptake corresponding to RT fields. Dose-effect relations for reduced uptake tended to be observed at 6 months after RT with mean decreases of 8.96% in regions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6% in regions at 30-35 Gy, 19.0% in regions at 40-45 Gy and 16.0% in regions at 50-55 Gy. CONCLUSIONS: Dose-effect relations for myocardial metabolic disorders tended to be observed. We may need to make an effort to reduce high-dose mediastinal RT to the myocardium in RT planning.
format Online
Article
Text
id pubmed-4407329
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44073292015-04-24 Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- Umezawa, Rei Takanami, Kentaro Kadoya, Noriyuki Nakajima, Yujiro Saito, Masahide Ota, Hideki Matsushita, Haruo Sugawara, Toshiyuki Kubozono, Masaki Yamamoto, Takaya Ishikawa, Yojiro Takeda, Ken Taki, Yasuyuki Takase, Kei Jingu, Keiichi Radiat Oncol Research BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with esophageal cancer before and six months after curative mediastinal RT. Single photon emission computed tomography (SPECT) images of pre-RT and post-RT were registered into RT dose distributions. The myocardium was contoured, and the regional RT dose was calculated. Normalization is required to compare pre- and post-RT SPECT images because the uptake pattern is changed due to the breathing level. Normalization was applied on the mean of SPECT counts in regions of the myocardium receiving less than 5 Gy. Relative values in each dose region (interval of 5 Gy) were calculated on the basis of this normalization for each patient. The reduction in the percent of relative values was calculated. RESULTS: Five patients were enrolled in this study. None of the patients had a past history of cardiac disease. The left ventricle was partially involved in RT fields in all patients. The patients received RT with median total doses of 60-66 Gy for the primary tumor and metastatic lymph nodes. Concomitant chemotherapy consisting of cisplatin or nedaplatin and 5-fluorouracil with RT was performed in 4 patients. All patients had reduced uptake corresponding to RT fields. Dose-effect relations for reduced uptake tended to be observed at 6 months after RT with mean decreases of 8.96% in regions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6% in regions at 30-35 Gy, 19.0% in regions at 40-45 Gy and 16.0% in regions at 50-55 Gy. CONCLUSIONS: Dose-effect relations for myocardial metabolic disorders tended to be observed. We may need to make an effort to reduce high-dose mediastinal RT to the myocardium in RT planning. BioMed Central 2015-04-21 /pmc/articles/PMC4407329/ /pubmed/25896887 http://dx.doi.org/10.1186/s13014-015-0410-z Text en © Umezawa et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Umezawa, Rei
Takanami, Kentaro
Kadoya, Noriyuki
Nakajima, Yujiro
Saito, Masahide
Ota, Hideki
Matsushita, Haruo
Sugawara, Toshiyuki
Kubozono, Masaki
Yamamoto, Takaya
Ishikawa, Yojiro
Takeda, Ken
Taki, Yasuyuki
Takase, Kei
Jingu, Keiichi
Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title_full Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title_fullStr Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title_full_unstemmed Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title_short Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
title_sort assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407329/
https://www.ncbi.nlm.nih.gov/pubmed/25896887
http://dx.doi.org/10.1186/s13014-015-0410-z
work_keys_str_mv AT umezawarei assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT takanamikentaro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT kadoyanoriyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT nakajimayujiro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT saitomasahide assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT otahideki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT matsushitaharuo assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT sugawaratoshiyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT kubozonomasaki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT yamamototakaya assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT ishikawayojiro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT takedaken assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT takiyasuyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT takasekei assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy
AT jingukeiichi assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy